Company news

Lyme Tests Launch

by

EpitogenX is thrilled to announce the launch of its cutting-edge Lyme Disease Diagnostic Kit. This advanced diagnostic tool is set to revolutionize Lyme disease research by providing unprecedented accuracy, reliability, and ease of use.

Lyme disease, caused by the Borrelia burgdorferi sensu lato (s.l.) complex, is of growing concern, with approximately 600,000 cases reported annually in the United States and Europe. Existing diagnostic methods primarily rely on symptom-based assessments, serology testing and exposure risk assessment. However, current methods have limitations, especially in the early stages of infection when timely diagnosis is critical. The two-tiered serology testing approach, consisting of ELISA followed by either an immunoblot or second ELISA, has proven effective in late-stage infections but lacks sensitivity for early localized Lyme disease where intervention is most effective.

To overcome the limitations of existing tests, we have developed a Lyme test utilizing a peptide-precision platform. This innovative strategy combines EpitoPredikt™ and Epitogen® technologies to identify and multiplex immunodominant-epitopes. Our assay utilises 120 specific and seropositive immunodominant epitopes from 37 Borrelia antigens corresponding to the main pathogenic species, B. burgdorferi, B. afzelii, B. garinii, and B. mayonii, leading to the creation of chimeric antigens to form the basis of the Lyme antibody test. As a result, the test exhibits a marked improvement in sensitivity and specificity which is validated using >300 samples including lyme (early and late cases), Cytomegalovirus, Epstein–Barr virus, Syphilis, Rheumatoid arthritis, Multiple sclerosis and healthy.

Key Features of the Lyme Kit:

  1. High Sensitivity and Specificity: Designed to deliver precise results, minimizing false positives and negatives, crucial for the accurate study of Lyme disease.
  2. Flexibility to Modify Antigen: we can customize the antigen to target a specific bacterial strain and relevant research objectives.
  3. Cost-Effective: Priced competitively to ensure accessibility for a wide range of research laboratories, making high-quality diagnostics more affordable.

 

Dr. Ayham Alnabulsi, Chief Technology Officer at EpitogenX, stated, “We are excited to introduce this highly advanced diagnostic kit to the research community. Our team has worked tirelessly to ensure that it meets the highest standards of accuracy and reliability. This kit represents a significant leap forward in Lyme disease research and has the potential to greatly enhance our understanding and management of this complex disease.”

The launch of the Lyme Disease Diagnostic Kit for RUO marks a significant milestone in our ongoing commitment to advancing medical research and improving diagnostic tools. We invite research institutions, laboratories, and scientists to explore the capabilities of our new kit and contribute to the global effort in combating Lyme disease.

 

For more information, please visit our Lyme product page.

For enquiries and orders, please email us at info@epitogenx.com.